⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28317880 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL28321164 | 0.69 | LMNA (0.31) | — | |
| SCHEMBL1051037 | 0.69 | TSHR (0.30) | — | |
| SCHEMBL3966052 | 0.67 | POLB (0.32) | — | |
| SCHEMBL1150701 | 0.67 | — | — | |
| SCHEMBL1758973 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL28339345 | 0.66 | BLM (0.32) | — | |
| SCHEMBL1759262 | 0.66 | — | — | |
| SCHEMBL14811423 | 0.63 | — | — | |
| SCHEMBL16517305 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107698660-B | imidazopyridine-6-formyl-Lys (Lys) -oligopeptides, their synthesis, activity and uses | 首都医科大学 | 2021-06-08 | — | — | CN | claimed |
| EP-4615573-A1 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024102625-A1 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4121429-A1 | CONDENSED PYRIDINE DERIVASTIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS | Merck Patent GmbH (DE) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021185789-A1 | CONDENSED PYRIDINE DERIVASTIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS | MERCK PATENT GMBH (DE) | 2021-09-23 | — | — | WO | disclosed |
| EP-2499140-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2499121-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. | F. Hoffmann-La Roche AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| EP-2499139-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011058473-A1 | N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057973-A1 | OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058474-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |